文献速递脑血管病

卡格列净与2型糖尿病患者的卒中

Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
PubMed 文献 · Stroke · 2019-01-01

CANVAS项目包含两项设计相似的临床试验,将10142例2型糖尿病且心血管高风险患者随机分配至卡格列净或安慰剂组。随访期间共309例卒中事件,卡格列净组卒中发生率为7.93/1000患者年,安慰剂组为9.62/1000患者年(HR 0.87,95%CI 0.69-1.09),对出血性卒中有显著减少(HR 0.43,95%CI 0.20-0.89)。

要点

  • 基线时有卒中或短暂性脑缺血发作者1958例(19%),卡格列净组卒中发生率7.93/1000患者年 vs 安慰剂组9.62/1000患者年(HR 0.87,95%CI 0.69-1.09)。
  • 出血性卒中30例,卡格列净组较安慰剂组显著减少(HR 0.43,95%CI 0.20-0.89)。
  • 缺血性卒中253例(HR 0.95,95%CI 0.74-1.22)及未确定类型卒中29例(HR 1.04,95%CI 0.48-2.22)无显著影响。

核心结论

  • CANVAS项目中卒中事件数太少,无法单独确定卡格列净对卒中的影响,但获益可能性大于危害。
  • 观察到的出血性卒中可能保护作用基于小样本数,需进一步研究。

研究设计与样本

  • CANVAS项目包含两项设计相似并实施的临床试验,随机分配10142例2型糖尿病且心血管高风险患者至卡格列净或安慰剂组。
  • 主要结局为主要不良心血管事件的复合终点,本报告关注的主要结局为致死性或非致死性卒中。

主要发现

  • 基线时有卒中或短暂性脑缺血发作者1958例(19%),这些个体年龄更大、女性更多、心力衰竭、心房颤动和微血管疾病发生率更高(所有P<0.001)。
  • 随访期间共309例卒中事件(基线有卒中或短暂性脑缺血发作者123例,无者186例),卡格列净组卒中发生率为7.93/1000患者年 vs 安慰剂组9.62/1000患者年(HR 0.87,95%CI 0.69-1.09)。
  • 缺血性卒中253例,卡格列净组 vs 安慰剂组无显著影响(HR 0.95,95%CI 0.74-1.22)。
  • 出血性卒中30例,卡格列净组较安慰剂组显著减少(HR 0.43,95%CI 0.20-0.89)。
  • 未确定类型卒中29例,卡格列净组 vs 安慰剂组无显著影响(HR 1.04,95%CI 0.48-2.22)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • CANVAS项目中卒中事件数太少,无法单独确定卡格列净对卒中的影响。
  • 观察到的出血性卒中可能保护作用基于小样本数,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- This study reports the detailed effects of canagliflozin on stroke, stroke subtypes, and vascular outcomes in participants with and without cerebrovascular disease (stroke or transient ischemic attack) at baseline from the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program. Methods- The CANVAS Program, comprising 2 similarly designed and conducted clinical trials, randomly assigned 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk to canagliflozin or placebo. Its primary outcome was a composite of major adverse cardiovascular events. The main outcome of interest for this report was fatal or nonfatal stroke. Additional exploratory outcomes were stroke subtypes and other vascular outcomes defined according to standard criteria. Results- There were 1 958 (19%) participants with prior stroke or transient ischemic attack at baseline. These individuals were older, more frequently women, and had higher rates of heart failure, atrial fibrillation, and microvascular disease (all P<0.001) compared with those without such a history. There were 309 participants with stroke events during follow-up (123 had prior stroke or transient ischemic attack at baseline and 186 did not), at a rate of 7.93/1000 patient-years among those assigned canagliflozin and 9.62/1000 patient-years among placebo (hazard ratio, 0.87; 95% CI, 0.69-1.09). Analysis of stroke subtypes found no effect on ischemic stroke (n=253, hazard ratio, 0.95; 95% CI, 0.74-1.22), a significant reduction for hemorrhagic stroke (n=30, hazard ratio, 0.43; 95% CI, 0.20-0.89) and no effect on undetermined stroke (n=29, hazard ratio, 1.04; 95% CI, 0.48-2.22). Effects on other cardiovascular outcomes were comparable among participants with and without stroke or transient ischemic attack at baseline. Conclusions- There were too few events in the CANVAS Program to separately define the effects of canagliflozin on stroke, but benefit is more likely than harm. The observed possible protective effect for hemorrhagic stroke was based on small numbers but warrants further investigation. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifiers: NCT01032629 and NCT01989754.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhou Z, Lindley RI, Rådholm K, et al. Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke. 2019. PMID: 30591006. doi:10.1161/STROKEAHA.118.023009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。